Pharma stocks decline amid Trump's prescription drug price cuts announcement
Synopsis The Nifty Pharma Index ended 0.2% higher Monday after tumbling almost 2.4% earlier in the day in response to Trump's remarks. The Sensex and Nifty jumped nearly 4%-posting their biggest single-day gains in four years. Of the 20 stocks in Nifty Pharma, 13 gained and seven declined. Mumbai: Several pharmaceutical shares underperformed on Monday despite a strong broad market rally, after US President Donald Trump announced plans to sign an executive order slashing prescription drug prices in the US to match those in favoured nations, implying cuts of 30% to 80%.
ADVERTISEMENT Sun Pharmaceuticals fell 3.2%, Ajanta Pharma slipped 2.3%, and Glenmark and Divi's Labs lost over 1% each. Biocon dipped 0.5%.
The Nifty Pharma Index ended 0.2% higher Monday after tumbling almost 2.4% earlier in the day in response to Trump's remarks. The Sensex and Nifty jumped nearly 4%-posting their biggest single-day gains in four years. Of the 20 stocks in Nifty Pharma, 13 gained and seven declined.
"The order implies a 30-80% expected cut to align US drug prices with other regulated markets. But such cuts are commercially unviable for pharma firms, especially those with low-double-digit margins," said Nikhil Ranka, CIO at Nuvama Alternates. "That's why companies like Sun Pharma, which derives around 40% revenues from the US, saw declines."Ranka said most pharma stocks rebounded after an initial knee-jerk reaction, as the proposed changes are not expected to be immediately enforceable or impactful. "Pharma stocks could resume their uptrend in the coming sessions," he said.Year-to-date, the Nifty Pharma Index is down 10%, compared with a 5% gain in the benchmark Nifty.
ADVERTISEMENT Bhavesh Gandhi, lead analyst for pharma and healthcare at YES Securities, said the proposed policy primarily targets the branded drugs segment, which accounts for 90% of the US market. Indian companies cater mostly to the remaining 10% - the generics space - where prices are already low."Sun Pharma, with some exposure to the branded segment, may face limited risk. But for now, the reaction is largely sentimental, and the real impact will depend on how earnings shape up," Gandhi said.
ADVERTISEMENT India Ratings and Research said Trump's executive order to reduce the prices of prescription drugs in the US, once implemented, will have a limited near-term impact on the Indian pharma companies, but it may have a bearing on their long-term capital allocation strategies. Most Indian companies operate on thin margins in the generic drugs segment, which limits scope for further price reductions. The proposed cuts are more likely to target the branded drugs segment, said analysts. 'Volumes may remain stable, but lower prices could squeeze margins and weigh on share prices,' said Dharmesh Kant, head of research at Cholamandalam Securities. He expects firms such as Sun Pharma, Aurobindo Pharma, and Cipla to be affected, though the extent of the impact is still uncertain.
(You can now subscribe to our ETMarkets WhatsApp channel)
Why gold prices could surpass $4,000: JP Morgan's bullish outlook explained
Why gold prices could surpass $4,000: JP Morgan's bullish outlook explained Cyient shares fall over 9% after Q4 profit declines, core business underperforms
Cyient shares fall over 9% after Q4 profit declines, core business underperforms L&T Technology Services shares slide 7% after Q4 profit dips
L&T Technology Services shares slide 7% after Q4 profit dips Trump-Powell standoff puts U.S. Rate policy in crosshairs: Who will blink first?
Trump-Powell standoff puts U.S. Rate policy in crosshairs: Who will blink first? SEBI warns of securities market frauds via YouTube, Facebook, X and more
SEBI warns of securities market frauds via YouTube, Facebook, X and more API Trading for All: Pi42 CTO Satish Mishra on How Pi42 is Empowering Retail Traders
API Trading for All: Pi42 CTO Satish Mishra on How Pi42 is Empowering Retail Traders Security, transparency, and innovation: What sets Pi42 apart in crypto trading
Security, transparency, and innovation: What sets Pi42 apart in crypto trading Bitcoin, Ethereum, or Altcoins? How investors are structuring their crypto portfolios, Avinash Shekhar explains
Bitcoin, Ethereum, or Altcoins? How investors are structuring their crypto portfolios, Avinash Shekhar explains The rise of Crypto Futures in India: Leverage, tax efficiency, and market maturity, Avinash Shekhar of Pi42 explains
The rise of Crypto Futures in India: Leverage, tax efficiency, and market maturity, Avinash Shekhar of Pi42 explains How Pi42 is simplifying crypto trading: CTO Satish Mishra on integrating technical & fundamental insights
NEXT STORY
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
5 minutes ago
- First Post
OPEC+ to hike oil output again in September amid Trump push to cut Russian imports
OPEC+ agreed on Sunday to raise oil production by 547,000 barrels per day for September, the latest in a series of accelerated output hikes to regain market share, as concerns mount over potential supply disruptions linked to Russia. read more A brief virtual meeting among eight OPEC+ countries on Sunday ended with an agreement to sharply increase oil production in September, even as the United States steps up pressure on India to curb imports of Russian oil, part of Washington's broader strategy to push Moscow towards peace talks with Ukraine. President Donald Trump has said he wants progress by August 8. In its post-meeting statement, OPEC+ pointed to strong global economic indicators and low inventory levels as key drivers behind its decision. Crude prices have remained robust, with Brent futures closing near $70 per barrel on Friday—up from a low of about $58 earlier this year, buoyed in part by seasonal demand. STORY CONTINUES BELOW THIS AD 'Given fairly strong oil prices at around $70, it does give OPEC+ some confidence about market fundamentals,' said Amrita Sen, co-founder of Energy Aspects, adding that the market structure was also indicating tight stocks. The eight participating nations will raise their collective output by 547,000 barrels per day in September, completing the accelerated reversal of a 2.2 million-bpd supply reduction imposed in 2023. The increase also accounts for a phased-in boost from the United Arab Emirates. OPEC+ sources told Reuters that the same group would reconvene on September 7, when they may evaluate whether to reintroduce another layer of cuts amounting to roughly 1.65 million bpd, measures that are officially extended through the end of next year. The broader OPEC+ coalition, comprising 10 non-OPEC producers including Russia and Kazakhstan, has historically curbed production to stabilise prices. However, the alliance pivoted this year, aiming to reclaim lost market share, a move aligned with calls from Trump urging the group to increase supply. The phased hikes began in April with a 138,000-bpd boost, followed by steeper increments of 411,000 bpd over the next three months, 548,000 bpd in August, and now 547,000 bpd for September. 'So far the market has been able to absorb very well those additional barrels also due to stockpiliing activity in China,' said Giovanni Staunovo of UBS. 'All eyes will now shift on the Trump decision on Russia this Friday." As well as the voluntary cut of about 1.65 million bpd from the eight members, OPEC+ still has a 2-million-bpd cut across all members, which also expires at the end of 2026. STORY CONTINUES BELOW THIS AD 'OPEC+ has passed the first test,' said Jorge Leon of Rystad Energy and a former OPEC official, as it has fully reversed its largest cut without crashing prices. 'But the next task will be even harder: deciding if and when to unwind the remaining 1.66 million barrels, all while navigating geopolitical tension and preserving cohesion." With inputs from agencies
&w=3840&q=100)
Business Standard
5 minutes ago
- Business Standard
US tariffs should not be cause for disengaging from trade talks, blocs
The fundamental challenge for the Indian economy is to increase productivity and competitiveness premium Business Standard Editorial Comment Mumbai Listen to This Article The tariff rate of 25 per cent, which United States (US) President Donald Trump has decided will be applied to Indian exports to the US, may not, eventually, be the final rate. It may effectively wind up being higher if he carries out his threat to add a surcharge related to India's increasing purchases of Russian oil. It may be lower if New Delhi's negotiators pull some sort of a broader deal together. It is also worth remembering that there will be multiple exceptions to this headline tariff rate. Some goods that compose a large part of India-US trade —
&w=3840&q=100)
Business Standard
5 minutes ago
- Business Standard
Collaboration for future: Isro and India will benefit from Nasa
Artemis signup allows Isro and the fast-growing Indian aerospace sector to bid for Nasa tenders and the famously frugal Indian engineering sector could find opportunities there and pick up new skills Business Standard Editorial Comment Mumbai Listen to This Article The successful launch of the Nisar (Nasa-Isro Synthetic Aperture Radar) satellite from the Satish Dhawan Space Centre marks the second big mission where the two space agencies have joined hands, coming soon after gaganaut Shubhanshu Shukla travelled to the International Space Station on the Axiom 4 mission. This may be the precursor to more cooperation between the agencies, given that India in 2023 signed up for the Artemis Accords. The Artemis Accords provide a common set of principles for civil exploration and use of outer space. While both agencies benefit from cooperation, the Indian Space Research Organisation (Isro) may benefit
